The US Food and Drug Administration has approved the first drug discovered entirely by artificial intelligence, marking a historic milestone for the pharmaceutical industry.
The drug, developed by Insilico Medicine for the treatment of idiopathic pulmonary fibrosis, was identified, designed, and optimised using AI systems. The entire process from target identification to Phase 2 trial completion took 30 months — less than a quarter of the industry average.
Traditional drug discovery typically takes 10-15 years and costs $2-3 billion per approved drug. Insilico's AI-first approach brought the timeline down to 2.5 years and the cost to approximately $150 million.
The implications for the pharmaceutical industry are profound. If AI can reliably reduce drug development timelines and costs by 80-90%, it could make treatments for rare diseases — previously uneconomical to develop — financially viable.
Major pharmaceutical companies are racing to build or acquire AI drug discovery capabilities. Pfizer, Roche, and AstraZeneca have all made significant acquisitions in this space during 2026.